Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study

Table 4 Univariate Cox proportional hazards analysis for posttransplant hepatitis B virus recurrence

Factor		Hazard ratio	95%CI	P value
Age (yr)	18-29 vs≥ 65	2.281	0.589-8.831	0.232
	30-39 vs≥ 65	1.441	0.438-4.736	0.547
	40-49 vs≥ 65	1.910	0.603-6.057	0.272
	50-64 vs≥ 65	1.657	0.522-5.262	0.392
Gender	Male vs Female	1.092	0.687-1.737	0.710
Pre-LT MELD score	6-9 vs 30-40	1.347	0.789-2.300	0.276
	10-19 vs 30-40	1.226	0.767-1.958	0.395
	20-29 vs 30-40	1.034	0.613-1.744	0.899
Pre-LT Child-Pugh score	5-6 vs 10-15	0.921	0.584-1.452	0.723
	7-9 vs 10-15	1.029	0.710-1.492	0.879
Pre-LT with HCC	Yes vs No	1.438	1.078-1.919	0.014
Pre-LT HBeAg status	Positive vs Negative	1.176	0.956-1.772	0.325
Pre-LT serum HBV DNA level
HBV DNA	Positive vs Negative	1.185	0.805-1.743	0.389
HBV DNA ≥ 105 copies/mL	Yes vs No	1.395	1.012-1.921	0.042
Pre-LT antiviral therapy
Using LAM	Yes vs No	0.930	0.697-1.241	0.622
Using ETV	Yes vs No	0.133	0.019-0.949	0.044
Using ADV	Yes vs No	0.328	0.046-2.333	0.265
Post-LT HBV prophylactic protocol	HBIG + LAM vs HBIG + ETV	2.949	1.210-7.188	0.017
	HBIG + ADV vs HBIG + ETV	1.714	0.410-7.171	0.461
Donor profiles
Donor source	Living donor vs Deceased donor	0.900	0.500-1.621	0.726
Donor gender	Male vs Female	0.564	0.298-1.067	0.078
Donor HBsAb positivity	Positive vs Negative	0.481	0.267-0.864	0.014
Donor HBcAb positivity	Positive vs Negative	1.598	0.786-3.247	0.195

LT: Liver transplantation; MELD: Model for end-stage liver disease; HCC: Hepatocellular carcinoma; HBeAg: Hepatitis B e antigen; HBV DNA: Hepatitis B virus deoxyribonucleic acid; LAM: Lamivudine; ETV: Entecavir; ADV: Adefovir dipivoxil; HBIG: Hepatitis B immunoglobulin; HBsAb: Hepatitis B surface antibody; HBcAb: Hepatitis B core antibody.